KLOW Blend

What Is KLOW Blend?

KLOW is a four-peptide co-formulated blend: BPC-157, TB-500, GHK-Cu (the dominant component by mass), and KPV. The four act on distinct mechanistic pathways in the tissue-repair and inflammation literature, which is the rationale for combining them. BPC-157 upregulates VEGFR2, drives local angiogenesis into damaged tissue, and restores tight-junction integrity in gut lining models. TB-500 sequesters G-actin monomers to enable cell migration into wound beds, upregulates VEGF, and dampens TNF-alpha and NF-kB pro-inflammatory signalling.

GHK-Cu delivers a copper(II) cofactor for lysyl oxidase (collagen and elastin crosslinking) and superoxide dismutase (antioxidant defence), and at the transcriptome level modulates roughly 4,000 human genes toward a younger expression profile per the 2010 Broad Institute Connectivity Map analysis. KPV is the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val), which enters cells via the PepT1 transporter and inhibits NF-kB and downstream cytokine production, with the strongest preclinical data in colitis, IBD, and skin-inflammation models. Tissue repair (BPC-157 and TB-500), structural matrix renewal (GHK-Cu), and anti-inflammatory signalling (KPV) are therefore represented in one formulation. No head-to-head trial of the four-way combination exists; the rationale is the sum of each component's documented effects, and no receptor competition or pathway antagonism among the four has been reported.